The
aldolases family is one of the main
enzymes involved in the process of glycolysis.
Aldolase C (ALDOC), which belongs to the
aldolase family, is found in normal brain tissue and is responsible for the repair of injured tissue. However, the role of ALDOC in
glioblastoma remains unclear. In this study, we data-mined in silico databases to evaluate
aldolase family members'
mRNA expression in
glioblastoma patient cohorts for determining its prognostic values. After that, we also performed immunohistochemical
stain (IHC) analysis to evaluate
protein expression levels of ALDOC in
glioblastoma tissues. From The
Cancer Genome Atlas (TCGA) database analyses, higher
mRNA expression levels in normal brain tissue compared to
glioblastoma was observed. In addition, compared to low-grade
glioma, ALDOC expression was significantly downregulated in high-grade
glioblastoma. Besides, the expression level of ALDOC was associated with molecular subtypes of
glioblastomas and recurrent status in several data sets. In contrast,
aldolase A (ALDOA) and
aldolase B (ALDOB) revealed no significant prognostic impacts in the
glioblastoma cohorts. Furthermore, we also proved that ALDOC
mRNA and
protein expression inversely correlated with non-mutated IDH1 expressions in
glioblastoma patient cohorts. Additionally, the concordance of low ALDOC and high non-mutated IDH1 expressions predicted a stronger poor prognosis in
glioblastoma patients compared to each of above tests presented alone. The plausible ALDOC and IDH1 regulatory mechanism was further elucidated. Our results support high ALDOC expression in
glioblastomas that might imply the mutated status of IDH1, less possibility of mesenchymal subtype, and predict a favorable prognosis.